A Phase 1 Study of Lirilumab (Antibody Against Killer Immunoglobulin-Like Receptor Antibody KIR2D; IPH2102) in Patients With Solid Tumors and Hematologic Malignancies
Oncotarget - United States
doi 10.18632/oncotarget.24832
Full Text
Open PDFAbstract
Available in full text
Categories
Date
March 19, 2018
Authors
Publisher
Impact Journals, LLC